Ionis Pharmaceuticals, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Quarterly filings show if a company is meeting financial targets and staying on track with investor expectations.
Earnings announcements reveal whether the company made money, spent less, or improved performance compared to previous periods.
Confirming previous financial forecasts signals management confidence that the company is on track with its plans.
Failed drug trials reduce chances of new product approval and revenue, which directly impacts a company's future growth.
New drug approvals create revenue opportunities and prove the company's research pipeline is producing commercial products.
Positive clinical data strengthens confidence in an approved drug's long-term safety and effectiveness for patients.
New board members with industry experience bring valuable expertise and connections that help guide company strategy.
Stocky reads Ionis Pharmaceuticals, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Ionis Pharmaceuticals, Inc.'s most recent tracked filing was a 10-Q on 29 Jul 2026: Company files quarterly report for period ended June 30, 2026.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.